

Argentina begins administering second Sputnik V doses

19 January 2021



Credit: Pixabay/CC0 Public Domain

Argentina's government began administering second doses of the Russian Sputnik V coronavirus vaccine Tuesday after receiving another shipment of 300,000 shots at the weekend.

Argentina began its immunization campaign on December 29 with the first 300,000 doses of the [vaccine](#) made by Russia's Gamaleya laboratory.

It is prioritizing [health care workers](#) in this first phase.

"The [immunization campaign](#) has been developing in a timely fashion," Health Minister Gines Gonzalez Garcia said.

The country of 44 million has recorded more than 1.8 million cases and almost 46,000 deaths from COVID-19.

Argentina was the first Latin American country, on December 23, to approve the "emergency use" of Sputnik V despite a lack of clinical trials.

The government has an agreement to purchase

another 19.4 million doses by the end of February with an option for an extra five million.

Argentina has committed to buying 51 million doses in total and has also signed deals to purchase the AstraZeneca/Oxford and Covax vaccines.

Negotiations are ongoing to procure the vaccine made by US pharmaceutical giant Pfizer with German biotechnology firm BioNTech.

The next stages of the immunization program will see the over 60s and people suffering from at least two illnesses receiving vaccines.

Meanwhile, Chile began immunizing its [general population](#) on Monday, starting with those over 80 or suffering from [chronic illnesses](#).

Chile started immunizing health care workers on December 24 and has signed deals to purchase 30 million doses.

It has reported 670,000 cases and 17,500 deaths amongst its 18 million population.

© 2021 AFP

APA citation: Argentina begins administering second Sputnik V doses (2021, January 19) retrieved 1 June 2022 from <https://medicalxpress.com/news/2021-01-argentina-sputnik-doses.html>

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.